Increasing Mirtazapine from 7.5mg to 15mg: Expected Effects
When increasing mirtazapine from 7.5mg to 15mg, you should expect improved antidepressant efficacy with paradoxically less sedation, but increased appetite and weight gain become more prominent. This counterintuitive dose-response relationship is unique to mirtazapine's pharmacology.
Pharmacological Changes at 15mg vs 7.5mg
At the lower 7.5mg dose, mirtazapine primarily exerts antihistamine (H1) effects, causing significant sedation but minimal antidepressant activity 1. When increased to 15mg—the FDA-recommended starting dose for depression 1—noradrenergic activity increases substantially, which:
- Reduces sedation compared to 7.5mg (paradoxical effect)
- Activates antidepressant mechanisms through norepinephrine and serotonin modulation
- Enhances therapeutic efficacy for depression, anxiety, and insomnia 2, 1
Clinical Effects You'll Observe
Therapeutic Benefits
- Antidepressant efficacy: 15mg represents the minimum therapeutic dose for depression, with response rates improving significantly over 7.5mg 3
- Sleep architecture improvement: Better quality sleep rather than just sedation 4, 5
- Appetite stimulation: More pronounced at 15mg, beneficial for patients with anorexia or weight loss 2, 6
- Anxiety reduction: Therapeutic anxiolytic effects emerge at 15mg 7
Side Effect Profile Changes
- Decreased daytime sedation: Patients often report feeling less drowsy during the day compared to 7.5mg 8
- Increased appetite and weight gain: This becomes the most prominent side effect at 15mg and higher doses 9, 10, 3
- Dry mouth, constipation: May become more noticeable 3
- Drowsiness: Still present but typically less problematic than at 7.5mg 8
Timing and Monitoring
The FDA label specifies dose changes should not occur more frequently than 1-2 week intervals to allow adequate assessment of response 1. At 15mg:
- Week 2: Expect 24.8% insomnia remission, 7.3% depression remission 3
- Week 6: Expect 62.4% insomnia remission, 41.3% depression remission 3
Critical Clinical Considerations
Weight gain warning: This is dose-dependent and can be substantial. In clinical trials, weight gain occurred in approximately 10% of patients at therapeutic doses 3. Counsel patients proactively, especially those with obesity, diabetes, or cardiovascular disease 6, 10.
Driving safety: Unlike 15mg, the 7.5mg dose significantly impairs driving performance 8. Paradoxically, patients may actually drive more safely at 15mg due to reduced sedation, though caution is still warranted during the first 1-2 weeks.
Discontinuation risk: If the patient discontinues, 23% may experience adverse events requiring gradual taper 11. The FDA mandates gradual dose reduction rather than abrupt cessation 1.
Special Populations Requiring Dose Adjustment
- Elderly patients: May need to remain at 7.5mg or increase more slowly due to 40% reduced clearance in elderly males 1
- Renal impairment: 30-50% reduction in clearance requires cautious titration 1
- Hepatic impairment: 30% decreased clearance necessitates slower titration 1
Drug Interactions at 15mg
Monitor for interactions with: